Compare Abbott Laboratories (ABT) vs Tempus AI (TEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Tempus AI — how do they compare? Abbott Laboratories trades at $95.65 (market cap $166.94B), while Tempus AI trades at $56.77 (market cap $10.79B). The key difference: Abbott Laboratories is far larger — about 15.5× Tempus AI's market cap, and Abbott Laboratories pays a 2.63% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| ABT | TEM | |
|---|---|---|
Market Cap | $166.94B | $10.79B |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $103.25 |
52-Week Low | $82.57 | $42.37 |
Enterprise Value | $193.69B | $11.47B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Tempus AI (TEM) trades at $60.70, up 0.71% with a bullish technical signal. The stock shows strong analyst support with 8 buy ratings and a $63.50 consensus target, though fundamentals reveal challenges with a -22.2% net margin and -$245M net loss for 2025. Recent FDA approvals and AI platform expansions drive positive sentiment, while cash flow remains dependent on financing activities.
Outlook remains cautiously optimistic given TEM's unique AI healthcare data platform and expanding partnerships, but investors face significant execution risks amid persistent losses. The stock's 7.85 P/S ratio reflects growth expectations, yet profitability concerns and high cash burn require careful monitoring for sustainable turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
